RA Drug Tested & FDA Orders Drug-Interaction Studies for Kayexalate

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Incyte Corp. New release: Baricitinib demonstrates superiority to adalimumab in improving signs and symptoms of rheumatoid arthritis in pivotal phase 3 study. 2015 Oct 14.
2. S. National Institutes of Health. A study in moderate to severe rheumatoid srthritis (RA-BEAM). ClinicalTrials.gov. 2015 May.
3. Barber J. Eli Lilly, Incyte’s baricitinib hits main goal of Phase III rheumatoid arthritis study. FirstWord Pharma. 2014 Dec 9.
4. Eli Lilly and Comp., Incyte Corp. New release: Baricitinib superior to methotrexate in reducing signs and symptoms in pivotal phase 3 study in patients with rheumatoid arthritis. 2015 Sep 29.
5. U.S. Food and Drug Administration. Safety alerts for human medical products: Kayexalate (sodium polystyrene sulfonate): Drug safety communication—FDA requires drug interaction studies. 2015 Oct 22.